LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

17.48 -1.58

Resumen

Variación precio

24h

Actual

Mínimo

17.33

Máximo

17.76

Métricas clave

By Trading Economics

Ingresos

6M

Ventas

162M

P/B

Media del Sector

6.079

35.664

BPA

0.52

Margen de beneficios

3.676

Empleados

1,780

EBITDA

-5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+39.43% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

2.8B

Apertura anterior

19.06

Cierre anterior

17.48

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

183 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 sept 2025, 22:39 UTC

Adquisiciones, fusiones, absorciones

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept 2025, 16:43 UTC

Principales Movimientos del Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept 2025, 16:42 UTC

Principales Movimientos del Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept 2025, 16:35 UTC

Principales Movimientos del Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept 2025, 22:48 UTC

Charlas de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Expects Commercial Launch in 2029

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 sept 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept 2025, 19:14 UTC

Charlas de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept 2025, 18:16 UTC

Charlas de Mercado

Gold Powers to New High -- Market Talk

15 sept 2025, 18:05 UTC

Charlas de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept 2025, 17:50 UTC

Adquisiciones, fusiones, absorciones

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept 2025, 17:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 17:10 UTC

Charlas de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept 2025, 16:52 UTC

Charlas de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

39.43% repunte

Estimación a 12 Meses

Media 25 USD  39.43%

Máximo 25 USD

Mínimo 25 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

183 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat